B cell-intrinsic TLR7 and TLR9 signatures define clinical phenotype and therapeutic response in lupus nephritis
OBJECTIVES: This study explores the expression of intracytoplasmic TLRs across diverse B cell subtypes in lupus, their association with renal activity, and their prognostic value. METHODS: We compared TLR7, TLR9, and MyD88 expression across peripheral B cell subtypes by flow cytometry, along with 29 cytokines serum levels from 28 LN patients and 26 lupus patients with extrarenal activity (NLN). After induction therapy, TLRs/MyD88 expression was reanalysed according to treatment response in LN. RESULTS: LN patients were characterised by higher frequency of MyD88+ B cells (86.5% vs 52.65%, p 0.04), predominantly in transitional cells (97.7% vs 58.7%, p 0.03). Treatment-adjusted analysis revealed the association of TLR7⁺ naïve B cells (OR 1.02, p 0.01) and TLR9 mean fluorescence intensity (MFI) in transitional B cells (OR 1.008, p 0.004) with LN. The latter, together with eotaxin (OR 1.01, p 0.01), constitute the proposed LN association model (OR 1.006 and 1.01 p 0.01, respectively). At 6-month follow-up, the responder group showed persistently elevated expression of TLR7 and TLR9 in naïve and atypical B-cell subsets, including double-negative (DN) and age-associated B cells (ABCs). The association model for renal response included TLR7 MFI in naïve B cells (OR 1 p 0.05) and TLR9 MFI in ABCs (OR 1.001 p 0.03). CONCLUSION: In LN, increased MyD88 and TLR7/TLR9 expression in early B-cell stages may promote autoreactive cell survival and differentiation into autoantibody-secreting cells, contributing to immune complex deposition and eotaxin-sustained renal inflammation. In contrast, higher TLR9 in TLR7-dependent subsets may exert a regulatory effect that, alongside induction therapy, favours nephritis resolution.
Authors
- Beatriz Alcalá‐Carmona (ORCID: https://orcid.org/0000-0002-0985-5609)
- Guillermo Juárez‐Vega (ORCID: https://orcid.org/0000-0002-0633-0567)
- Nancy R. Mejía‐Domínguez (ORCID: https://orcid.org/0000-0002-5788-4586)
- José Luis Maravillas‐Montero (ORCID: https://orcid.org/0000-0003-3755-662X)
- Diana Gómez‐Martín (ORCID: https://orcid.org/0000-0002-1807-0045)
- Samuel Govea‐Pelaéz (ORCID: https://orcid.org/0009-0000-8475-0287)
- Jennifer Tiaré Balderas-Miranda (ORCID: https://orcid.org/0000-0002-2364-7697)
- David Eduardo Meza-Sánchez (ORCID: https://orcid.org/0000-0003-0392-296X)
- Fabiola Cassiano-Quezada (ORCID: https://orcid.org/0000-0001-7400-7545)
- Jiram José Torres-Ruiz (ORCID: https://orcid.org/0000-0002-7882-1488)
- Mauricio Arvizu-Hernández
- Michelle Patricia Loeza-Uribe (ORCID: https://orcid.org/0009-0003-9329-7850)
- María José Ostos-Prado (ORCID: https://orcid.org/0009-0000-9347-8705)
- Yatzil Reyna-Juárez (ORCID: https://orcid.org/0000-0002-9558-893X)
- Karina Santana-de Anda (ORCID: https://orcid.org/0000-0002-3618-3545)
- Norma Uribe (ORCID: https://orcid.org/0000-0002-4429-1298)
- Álvaro Sierra-Salazar
Institutions
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Universidad Nacional Autónoma de México (MX)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- Rheumatology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/rheumatology/keag649
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00